Fig. 1
From: Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer
Kaplan–Meier estimates of OS and DFS according to JMJD6 expression groups. a JMJD6 protein expression in ovarian cancer tissues detected by immunohistochemistry analysis. a Low staining, b Intermediate staining, c Strong staining of JMJD6 protein, d Negative control (normal adjacent tissues of ovarian cancer), e Primary antibody-free negative control, magnification, ×200. b Overall survival of serous ovarian cancer, log-rank test: p = 0.0002. c Disease-free survival of serous ovarian cancer, log-rank test: p = 0.0087. d Overall survival of mucinous ovarian cancer, log-rank test: p < 0.0001. e Disease-free survival of mucinous ovarian cancer, log-rank test: p < 0.0001
